SCHEMBL22777429

SCHEMBL22777429

CCOC(=O)/C=C/CN1CCSC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.41
HCAR2 Q8TDS4 1/20 0.40
ALDH1A1 P00352 3/20 0.37
DPP4 P27487 2/20 0.33
TTR P02766 1/20 0.33
CA12 O43570 1/20 0.33
CA1 P00915 1/20 0.33
CA2 P00918 1/20 0.33
CA7 P43166 1/20 0.33
CA9 Q16790 1/20 0.33
CA14 Q9ULX7 1/20 0.33
MAPK1 P28482 1/20 0.32
CYP3A4 P08684 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
KDM4E B2RXH2 1/20 0.32
HPGD P15428 1/20 0.32
RECQL P46063 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RAB9A P51151 1/20 0.31
F13A1 P00488 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22777432 1.00 MAPT (0.41) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL30154189 0.79 MAPT (0.46) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL25811871 0.79 MAPT (0.46) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL6621859 0.78 MAPT (0.45) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL6621854 0.78 MAPT (0.45) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL2840343 0.77 INMT (0.36) NPSR1KDM4EDPP7
SCHEMBL2840340 0.77 INMT (0.36) NPSR1KDM4EDPP7
SCHEMBL23178554 0.76 MAPT (0.44) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL16144128 0.75 MAPT (0.42) MAPTHCAR2ALDH1A1DPP4TTR
SCHEMBL19533587 0.75 TSHR (0.49) MAPTHCAR2ALDH1A1CYP3A4NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME JANSSEN PHARMACEUTICA NV (BE) 2022-08-11 US disclosed
EP-3983401-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME Arkuda Therapeutics (US) 2022-04-20 EP disclosed
WO-2020252222-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME ARKUDA THERAPEUTICS (US) 2020-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220251084-A1 PROGRANULIN MODULATORS AND METHODS OF USING THE SAME GRN, PRNP, PSEN2 MAPT 16/4885HCAR2 4196/4885ALDH1A1 4845/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.